Flexion Therapeutics INC Com (FLXN) Shareholder Gilder Gagnon Howe & Co LLC Upped Stake by $7.47 Million

September 12, 2017 - By Nellie Frank

Investors sentiment increased to 2.54 in Q4 2016. Its up 1.00, from 1.54 in 2016Q3. It improved, as 8 investors sold FLXN shares while 16 reduced holdings. 19 funds opened positions while 42 raised stakes. 21.98 million shares or 21.15% more from 18.14 million shares in 2016Q3 were reported. Legal & General Gp Public Ltd accumulated 6,811 shares or 0% of the stock. Alyeska Group Inc Limited Partnership has 250,000 shares for 0.04% of their portfolio. Natl Bank Of America De holds 0% or 16,163 shares. Blackrock Limited Liability Company holds 13,762 shares or 0% of its portfolio. The New York-based Gilder Gagnon Howe And Ltd Llc has invested 1.64% in Flexion Therapeutics Inc (NASDAQ:FLXN). Blackrock has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Citigroup reported 28,692 shares. Wall Street Assoc accumulated 84,700 shares or 1.06% of the stock. Gam Hldg Ag accumulated 130,500 shares or 0.04% of the stock. Grp has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Driehaus Mgmt Ltd Llc invested in 0.3% or 449,707 shares. Invesco has 30,804 shares. Metropolitan Life Ny holds 0% or 18,264 shares in its portfolio. Northern Trust has 338,642 shares for 0% of their portfolio. Parametric Portfolio Associate Lc holds 0% in Flexion Therapeutics Inc (NASDAQ:FLXN) or 15,419 shares.

Since March 17, 2017, it had 3 buys, and 3 sales for $102,399 activity. 3,000 shares valued at $69,000 were sold by DRISCOLL FREDERICK W on Thursday, March 23. $85,048 worth of stock was bought by COLELLA SAMUEL D on Monday, June 5. 5,000 shares valued at $86,152 were bought by Clayman Michael D. on Monday, June 5. Bodick Neil sold 6,830 shares worth $129,448.

Gilder Gagnon Howe & Co Llc increased its stake in Flexion Therapeutics Inc Com (FLXN) by 9.86% based on its latest 2016Q4 regulatory filing with the SEC. Gilder Gagnon Howe & Co Llc bought 392,904 shares as the company’s stock declined 8.37% while stock markets rallied. The institutional investor held 4.38 million shares of the health care company at the end of 2016Q4, valued at $83.29 million, up from 3.99M at the end of the previous reported quarter. Gilder Gagnon Howe & Co Llc who had been investing in Flexion Therapeutics Inc Com for a number of months, seems to be bullish on the $752.65M market cap company. The stock declined 1.71% or $0.41 reaching $23.59 on the news. About 109,023 shares traded. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 82.02% since September 12, 2016 and is uptrending. It has outperformed by 65.32% the S&P500.

Gilder Gagnon Howe & Co Llc, which manages about $6.26 billion and $5.07 billion US Long portfolio, decreased its stake in 2U Inc Com Usd0.001 (NASDAQ:TWOU) by 200,258 shares to 3.55M shares, valued at $107.12 million in 2016Q4, according to the filing. It also reduced its holding in Lumentum Hldgs Inc Com by 366,580 shares in the quarter, leaving it with 1.70M shares, and cut its stake in Epam Sys Inc Com Usd0.001 (NYSE:EPAM).

More notable recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Seekingalpha.com which released: “Flexion Therapeutics Inc.: Teeing up to disrupt the osteoarthritis market” on August 24, 2017, also Globenewswire.com with their article: “Flexion Therapeutics Named One of Boston Business Journal’s Best Places to Work” published on June 23, 2017, Fool.com published: “Here’s Why Flexion Therapeutics Inc. Skyrocketed Today” on March 23, 2017. More interesting news about Flexion Therapeutics Inc (NASDAQ:FLXN) were released by: Fool.com and their article: “Why Flexion Therapeutics Shares Shot 12.8% Higher in July” published on August 07, 2017 as well as Seekingalpha.com‘s news article titled: “Flexion Therapeutics: Updates To Thesis” with publication date: August 27, 2017.

Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage

Among 9 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 13 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Buy” rating by Lake Street on Thursday, July 21. The rating was initiated by Cantor Fitzgerald with “Buy” on Wednesday, November 4. The firm has “Outperform” rating given on Wednesday, June 29 by BMO Capital Markets. The stock has “Buy” rating by RBC Capital Markets on Monday, September 11. The firm has “Outperform” rating given on Tuesday, May 3 by Wells Fargo. The firm has “Buy” rating given on Monday, June 26 by BMO Capital Markets. As per Monday, June 12, the company rating was maintained by Cantor Fitzgerald. Needham maintained the stock with “Buy” rating in Wednesday, September 9 report. The firm has “Buy” rating by RBC Capital Markets given on Friday, July 7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.